SEC Form 4 · accession 0001209191-15-075102

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Oct 7, 2015

Accepted (ET)

Oct 9, 2015 · 5:16 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Oct 7, 2015	M	10,400	$35.64	A	355,684	D
Common Stock^F2,F3	Oct 7, 2015	S	900	$107.23	D	354,784	D
Common Stock^F2,F4	Oct 7, 2015	S	4,300	$108.74	D	350,484	D
Common Stock^F2,F5	Oct 7, 2015	S	1,300	$109.60	D	349,184	D
Common Stock^F2,F6	Oct 7, 2015	S	2,500	$110.67	D	346,684	D
Common Stock^F2,F7	Oct 7, 2015	S	1,400	$111.93	D	345,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	122,700	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F8	$35.64	Oct 7, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	167,200	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $107.23 (range $106.92 to $107.69).
F4Open market sales reported on this line occurred at a weighted average price of $108.74 (range $108.20 to $109.11).
F5Open market sales reported on this line occurred at a weighted average price of $109.60 (range $109.24 to $110.23).
F6Open market sales reported on this line occurred at a weighted average price of $110.67 (range $110.24 to $111.09).
F7Open market sales reported on this line occurred at a weighted average price of $111.93 (range $111.52 to $112.42).
F8Fully vested.